Clinical Trial Update: A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study of linperlisib in combination with rituximab in relapsed/refractory indolent non-Hodgkin lymphoma; the study is not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Linperlisib (linperlisib)
• Rituximab (rituximab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Relapsed/Refractory Indolent NHL | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING